Information Provided By: 
Fly News Breaks for April 3, 2018
SRNE
Apr 3, 2018 | 07:14 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Sorrento Therapeutics to $40 from $38 saying the recently completed convertible note financing "provides ample runway." The company now has a sufficient cash runway to fund operations for at least the next 24 months, which removes a near-term overhang, Selvaraju tells investors in a research note. He reiterates a Buy rating on Sorrento.
News For SRNE From the Last 2 Days
There are no results for your query SRNE
